Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	1
Methcathinone (1237)	1
Aminorex (1585)	1
Alpha-ethyltryptamine (7249)	1
Lysergic acid diethylamide (7315)	1
Tetrahydrocannabinols (7370)	1
4-Bromo-2,5-	1
dimethoxyamphetamine (7391).	
4-Bromo-2,5-	I
dimethoxyphenethylamine	
(7392). 2,5-Dimethoxyamphetamine	ı
(7396).	
3,4-Methylenedioxyamphetamine	1
(7400).	
N-Hydroxy-3,4-	I
methylenedioxyamphetamine	
(7402).	
3,4-Methylenedioxy-N-	I
ethylamphetamine (7404). 3,4-	ı
Methylenedioxymethamphetam-	
ine (MDMA) (7405).	
Psilocybin (7437)	1
5-Methoxy-N,N-	Ì
diisopropyltryptamine (7439).	
1-[1-(2-	1
Thienyl)cyclohexyl]piperidine	
(TCP) (7470).	
N-Benzylpiperazine (BZP) (7493)	
Heroin (9200)	1
Normorphine (9313) Amphetamine (1100)	l II
Methamphetamine (1105)	
Nabilone (7379)	l'i
1-Phenylcyclohexylamine (7460)	l ii
Phencyclidine (7471)	ii
Cocaine (9041)	II
Codeine (9050)	II
Ecgonine (9180)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Meperidine (9230)	II
Metazocine (9240)	l II
Methadone (9250)	II II
Morphine (9300)	II II
Thebaine (9333)	II II
Levo-alphacetylmethadol (9648) Remifentanil (9739)	
Carfentanii (9743)	l ii
Fentanyl (9801)	l ii

The company plans to manufacture reference standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma

Aldrich Research Biochemicals, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: May 22, 2013.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration

[FR Doc. 2013–12832 Filed 5–29–13; 8:45 am] BILLING CODE 4410–09–P

#### **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

Manufacturer of Controlled Substances; Notice of Registration; Mallinckrodt, LLC.

By Notice dated February 8, 2013, and published in the **Federal Register** on February 21, 2013, 78 FR 12102, Mallinckrodt, LLC., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Tetrahydrocannabinols (7370)	
4-Anilino-N-phenethyl-4-piperidine (8333).	ii
Codeine (9050)	Ш
Dihydrocodeine (9120)	Ш
Oxycodone (9143)	II
Hydromorphone (9150)	Ш
Diphenoxylate (9170)	II
Ecgonine (9180)	II
Hydrocodone (9193)	Ш
Levorphanol (9220)	II
Meperidine (9230)	Ш
Methadone (9250)	II
Methadone intermediate (9254)	II
Dextropropoxyphene, bulk (non—dosage forms) (9273).	II
Morphine (9300)	П

	1
Drug	Schedule
Oripavine (9330)	

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Mallinckrodt, LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Mallinckrodt, LLC., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: May 22, 2013.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–12831 Filed 5–29–13; 8:45 am]

#### **DEPARTMENT OF LABOR**

## Office of the Secretary

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Reporting and Performance Standards for Workforce Investment Act Indian and Native American Programs

**ACTION:** Notice.

SUMMARY: On May 31, 2013, the Department of Labor (DOL) will submit the Employment and Training (ETA) sponsored information collection request (ICR) revision titled, "Reporting and Performance Standards for Workforce Investment Act Indian and Native American Programs," to the Office of Management and Budget